Literature DB >> 34251989

The journey of SARS-CoV-2 in human hosts: a review of immune responses, immunosuppression, and their consequences.

Amal F Alshammary1, Abdulrahman M Al-Sulaiman2.   

Abstract

Coronavirus disease 2019 (n class="Disease">COVID-19) is a highly infectious viral disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Laboratory findings from a significant number of patients with COVID-19 indicate the occurrence of leukocytopenia, specifically lymphocytopenia. Moreover, infected patients can experience contrasting outcomes depending on lymphocytopenia status. Patients with resolved lymphocytopenia are more likely to recover, whereas critically ill patients with signs of unresolved lymphocytopenia develop severe complications, sometimes culminating in death. Why immunodepression manifests in patients with COVID-19 remains unclear. Therefore, the evaluation of clinical symptoms and laboratory findings from infected patients is critical for understanding the disease course and its consequences. In this review, we take a logical approach to unravel the reasons for immunodepression in patients with COVID-19. Following the footprints of the virus within host tissues, from entry to exit, we extrapolate the mechanisms underlying the phenomenon of immunodepression.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; coronavirus; cytokine storm; immunosuppression; leukocytopenia; lymphocytopenia; severe acute respiratory syndrome coronavirus 2

Year:  2021        PMID: 34251989     DOI: 10.1080/21505594.2021.1929800

Source DB:  PubMed          Journal:  Virulence        ISSN: 2150-5594            Impact factor:   5.882


  8 in total

1.  Extracellular Nucleotides and Histamine Suppress TLR3- and RIG-I-Mediated Release of Antiviral IFNs from Human Airway Epithelial Cells.

Authors:  Timothy S Kountz; Assel Biyasheva; Robert P Schleimer; Murali Prakriya
Journal:  J Immunol       Date:  2022-04-22       Impact factor: 5.426

2.  T-Cell Subsets and Interleukin-10 Levels Are Predictors of Severity and Mortality in COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Amal F Alshammary; Jawaher M Alsughayyir; Khalid K Alharbi; Abdulrahman M Al-Sulaiman; Haifa F Alshammary; Heba F Alshammary
Journal:  Front Med (Lausanne)       Date:  2022-04-28

3.  A study on the willingness and influencing factors of novel coronavirus vaccination among medical personnel in North China.

Authors:  Jinqi Hao; Huimin Liu; Jihai Shi; Qiufeng Wang; Xiaoyou Su; Zhengyang Shi; Yanqin Yu; Bo Liu; Youlin Qiao
Journal:  Hum Vaccin Immunother       Date:  2022-04-04       Impact factor: 4.526

4.  Vaccine-Related Lymph Nodes: The Emerging Pitfalls of 18F-Fluorocholine and 68Ga-PSMA-11 PET/CT in the Era of COVID-19 Vaccination.

Authors:  Loic Ah-Thiane; Ludovic Ferrer; Bruno Maucherat; Vincent Fleury; Maelle Le Thiec; Daniela Rusu; Caroline Rousseau
Journal:  Clin Nucl Med       Date:  2022-04-27       Impact factor: 10.782

5.  Analytical characterization of the SARS-CoV-2 EURM-017 reference material.

Authors:  James Freeman; Kalen Olson; Justin Conklin; Victoria Shalhoub; Bryan A Johnson; Nathen E Bopp; Diana Fernandez; Vineet D Menachery; Patricia V Aguilar
Journal:  Clin Biochem       Date:  2021-12-18       Impact factor: 3.281

6.  Cytotoxic T-Cell-Based Vaccine against SARS-CoV-2: A Hybrid Immunoinformatic Approach.

Authors:  Alexandru Tirziu; Virgil Paunescu
Journal:  Vaccines (Basel)       Date:  2022-01-30

Review 7.  Regulated necrosis in COVID-19: A double-edged sword.

Authors:  Chen Sun; Yunze Han; Ruoyu Zhang; Simon Liu; Jing Wang; Yuqing Zhang; Xuemei Chen; Chao Jiang; Junmin Wang; Xiaochong Fan; Jian Wang
Journal:  Front Immunol       Date:  2022-08-25       Impact factor: 8.786

8.  Entrectinib-A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells.

Authors:  Alejandro Peralta-Garcia; Mariona Torrens-Fontanals; Tomasz Maciej Stepniewski; Judith Grau-Expósito; David Perea; Vikram Ayinampudi; Maria Waldhoer; Mirjam Zimmermann; María J Buzón; Meritxell Genescà; Jana Selent
Journal:  Int J Mol Sci       Date:  2021-12-18       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.